145 related articles for article (PubMed ID: 15607361)
41. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
42. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.
Tomiyasu H; Watanabe M; Sugita K; Goto-Koshino Y; Fujino Y; Ohno K; Sugano S; Tsujimoto H
Anticancer Res; 2013 Dec; 33(12):5317-23. PubMed ID: 24324065
[TBL] [Abstract][Full Text] [Related]
43. [Study on the relationship between breast cancer resistance protein expression and 5-fluorouracil resistance].
Yuan JH; Cheng JQ; Ke YB; Ji NN; Zhou JM; Zhou L; Huang HY; Yang LQ; Liu JJ; Xu XY; Zhuang ZX
Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Jul; 42(7):506-10. PubMed ID: 19035187
[TBL] [Abstract][Full Text] [Related]
44. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
45. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
Nakanishi T; Bailey-Dell KJ; Hassel BA; Shiozawa K; Sullivan DM; Turner J; Ross DD
Cancer Res; 2006 May; 66(10):5007-11. PubMed ID: 16707421
[TBL] [Abstract][Full Text] [Related]
46. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
47. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
48. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
49. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
50. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
51. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor.
Yeboah D; Sun M; Kingdom J; Baczyk D; Lye SJ; Matthews SG; Gibb W
Can J Physiol Pharmacol; 2006 Dec; 84(12):1251-8. PubMed ID: 17487233
[TBL] [Abstract][Full Text] [Related]
52. [Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Li X; Li Y; Yang SE; Ma Y; Wen SJ; Guo L; Guli KZ; Zhao B; Liu W; Hu X
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):916-20. PubMed ID: 22340101
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
[TBL] [Abstract][Full Text] [Related]
54. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
55. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
[TBL] [Abstract][Full Text] [Related]
56. Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Nakano H; Nakamura Y; Soda H; Kamikatahira M; Uchida K; Takasu M; Kitazaki T; Yamaguchi H; Nakatomi K; Yanagihara K; Kohno S; Tsukamoto K
Cancer; 2008 Mar; 112(5):1122-30. PubMed ID: 18219662
[TBL] [Abstract][Full Text] [Related]
57. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype.
Damiani D; Tiribelli M; Calistri E; Geromin A; Chiarvesio A; Michelutti A; Cavallin M; Fanin R
Haematologica; 2006 Jun; 91(6):825-8. PubMed ID: 16704962
[TBL] [Abstract][Full Text] [Related]
58. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
59. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
Yuan JH; He ZM; Yu YH; Chen ZC
Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
[TBL] [Abstract][Full Text] [Related]
60. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
